Immuneering Corp Cl A (IMRX) Stock Price, Quote & News

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inh...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8080

Website: immuneering.com

Address:

245 Main Street, Second Floor, Cambridge, United States

combat_cannabis Aug. 4 at 1:22 PM

$IMRX in at 4.08 w stoploss under 4$ and the pump has arrived boys!! Let’s go!

0 · Reply

OptimistJP Aug. 4 at 10:01 AM

$IMRX Extended hours $4.15-0.02 (-0.48%) Bid x Size $4.03 x 600 Ask x Size $5.20 x 100

0 · Reply

longDstyle Aug. 3 at 10:58 PM

$IMRX grabbed 20k shares in the low $4’s. Holding until the 3 month readout (potentially longer)

0 · Reply

combat_cannabis Aug. 3 at 2:10 PM

$IMRX nice work bulls I’m in at 4.08 with stop under 4$

0 · Reply

JuggernautRaider Aug. 3 at 10:33 AM

$TNXP $ALT $IMRX $CCCC I’m a biopharma bull in a cage of rage 😡 🇺🇸 💪 🐂 🧫

0 · Reply

speed717 Aug. 1 at 5:51 PM

$IMRX Nobody mentioned the $1MM spent on 225,000 shares by CFO. Why?

1 · Reply

JuggernautRaider Aug. 1 at 1:40 PM

$MIST $TNXP $ALT $IMRX “Families are always rising and falling in America.” ~Hawthrone

2 · Reply

longDstyle Jul. 31 at 3:48 PM

$IMRX bought another chunk today

0 · Reply

longDstyle Jul. 31 at 4:02 AM

$IMRX does anyone know a timeframe when they will report the 3 month readout ?

0 · Reply

a0Br0 Jul. 30 at 11:51 PM

$IMRX is this ah pump just gonna fade in the PM?

0 · Reply

Immuneering publishes preclinical data on atebimetinib in Cancer Research

Jul 21, 2026, 4:05 PM EDT - 13 days ago

Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Jul 17, 2026, 4:05 PM EDT - 17 days ago

Immuneering Corporation Announces Grants of Inducement Awards

2026-07-08T11:50:16.000Z - 27 days ago

Immuneering initiated with an Overweight at Cantor Fitzgerald

2026-06-15T11:43:43.000Z - 7 weeks ago

Immuneering appoints Andrew Gengos as CFO

Jun 15, 2026, 7:30 AM EDT - 7 weeks ago

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Jun 11, 2026, 11:00 AM EDT - 7 weeks ago

Immuneering Transcript: AGM 2026

Jun 11, 2026, 7:30 AM EDT - 7 weeks ago

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

2026-06-01T13:26:29.000Z - 2 months ago

Immuneering announces updated clinical data from atebimetinib combination trial

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Immuneering Transcript: Study result

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Immuneering Press release: Study result

Jun 1, 2026, 7:30 AM EDT - 2 months ago

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

May 21, 2026, 5:00 PM EDT - 2 months ago

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

2026-05-15T14:03:04.000Z - 2 months ago

Immuneering reports Q1 EPS (21c), consensus (25c)

May 15, 2026, 7:35 AM EDT - 2 months ago

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026, 7:30 AM EDT - 2 months ago

Immuneering Earnings release: Q1 2026

May 15, 2026, 7:30 AM EDT - 2 months ago

Immuneering Quarterly report: Q1 2026

2026-04-21T21:01:42.000Z - 3 months ago

Immuneering announces updated data from Phase 2a trial for atebimetinib

Apr 21, 2026, 4:05 PM EDT - 3 months ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

2026-04-20T14:04:20.000Z - 3 months ago

Immuneering announces presentation of new genetic data at 2026 AACR

Apr 20, 2026, 9:00 AM EDT - 3 months ago

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Immuneering Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Immuneering Proxy statement: Proxy filing

Apr 13, 2026, 3:45 PM EDT - 4 months ago

Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:05 PM EDT - 4 months ago

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 17, 2026, 4:35 PM EDT - 4 months ago

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 9, 2026, 3:40 PM EDT - 5 months ago

Immuneering Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T10:56:34.000Z - 5 months ago

Immuneering price target lowered to $12 from $13 at Piper Sandler

Mar 6, 2026, 8:00 AM EST - 5 months ago

Immuneering Annual report: Q4 2025

Mar 6, 2026, 8:00 AM EST - 5 months ago

Immuneering Earnings release: Q4 2025

2026-03-06T12:52:29.000Z - 5 months ago

Immuneering reports Q4 EPS (18), consensus (31c)

2026-03-06T12:52:10.000Z - 5 months ago

Immuneering sees cash runway into 2029

Mar 6, 2026, 7:45 AM EST - 5 months ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 5 months ago

Immuneering to Present at the Leerink Global Healthcare Conference

Feb 26, 2026, 10:00 AM EST - 5 months ago

Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 4:05 PM EST - 5 months ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-08T17:55:15.000Z - 7 months ago

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

RVMD

2026-01-07T23:45:14.000Z - 7 months ago

Immuneering reports ‘positive’ survival, safety data from atebimetinib trial

Jan 7, 2026, 4:30 PM EST - 7 months ago

Immuneering Transcript: Study Result

Jan 7, 2026, 4:30 PM EST - 7 months ago

Immuneering Press release: Study Result

Jan 7, 2026, 4:00 PM EST - 7 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

2026-01-07T19:25:26.000Z - 7 months ago

Immuneering management to meet with Oppenheimer

Dec 23, 2025, 8:00 AM EST - 8 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 17, 2025, 4:05 PM EST - 8 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 16, 2025, 8:00 AM EST - 8 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 4, 2025, 11:10 AM EST - 8 months ago

Immuneering Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 12, 2025, 4:30 PM EST - 9 months ago

Immuneering Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Immuneering Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Immuneering Earnings release: Q3 2025

Nov 12, 2025, 4:05 PM EST - 9 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 4, 2025, 4:05 PM EST - 9 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Sep 26, 2025, 4:01 PM EDT - 11 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 25, 2025, 12:08 AM EDT - 11 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 11 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:01 PM EDT - 11 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 16, 2025, 7:00 AM EDT - 11 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 10, 2025, 7:00 AM EDT - 11 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 3, 2025, 8:00 AM EDT - 11 months ago

Immuneering Registration statement: Registration Filing

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Immuneering Announces Closing of $25 Million Private Placement

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Announces $25 Million Private Placement

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Immuneering Registration statement: Registration Filing

Aug 13, 2025, 12:00 AM EDT - 1 year ago

Immuneering Quarterly report: Q2 2025

Aug 13, 2025, 12:00 AM EDT - 1 year ago

Immuneering Earnings release: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Transcript: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Press release: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Slides: Study Update

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Immuneering Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Quarterly report: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Earnings release: Q1 2025

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Apr 9, 2025, 1:30 PM EDT - 1 year ago

Immuneering Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Annual report: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Earnings release: Q4 2024

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Feb 12, 2025, 2:40 PM EST - 1 year ago

Immuneering Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Transcript: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Press release: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Slides: Study Result

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 5, 2024, 1:00 PM EST - 1 year ago

Immuneering Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Earnings release: Q3 2024

Sep 12, 2024, 4:30 PM EDT - 2 years ago

Immuneering Transcript: Study Update

Sep 12, 2024, 4:30 PM EDT - 2 years ago

Immuneering Press release: Study Update

Sep 12, 2024, 4:05 PM EDT - 2 years ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 6, 2024, 10:00 AM EDT - 2 years ago

Immuneering Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immuneering Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immuneering Earnings release: Q2 2024

Jul 31, 2024, 4:05 PM EDT - 2 years ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jun 5, 2024, 4:30 PM EDT - 2 years ago

Immuneering Transcript: Jefferies 2024 Global Healthcare Conference

May 7, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:00 PM EDT - 2 years ago

Immuneering Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Immuneering Earnings release: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Immuneering Recognizes Melanoma Awareness Month

combat_cannabis Aug. 4 at 1:22 PM

$IMRX in at 4.08 w stoploss under 4$ and the pump has arrived boys!! Let’s go!

0 · Reply

OptimistJP Aug. 4 at 10:01 AM

$IMRX Extended hours $4.15-0.02 (-0.48%) Bid x Size $4.03 x 600 Ask x Size $5.20 x 100

0 · Reply

longDstyle Aug. 3 at 10:58 PM

$IMRX grabbed 20k shares in the low $4’s. Holding until the 3 month readout (potentially longer)

0 · Reply

combat_cannabis Aug. 3 at 2:10 PM

$IMRX nice work bulls I’m in at 4.08 with stop under 4$

0 · Reply

JuggernautRaider Aug. 3 at 10:33 AM

$TNXP $ALT $IMRX $CCCC I’m a biopharma bull in a cage of rage 😡 🇺🇸 💪 🐂 🧫

0 · Reply

speed717 Aug. 1 at 5:51 PM

$IMRX Nobody mentioned the $1MM spent on 225,000 shares by CFO. Why?

1 · Reply

JuggernautRaider Aug. 1 at 1:40 PM

$MIST $TNXP $ALT $IMRX “Families are always rising and falling in America.” ~Hawthrone

2 · Reply

longDstyle Jul. 31 at 3:48 PM

$IMRX bought another chunk today

0 · Reply

longDstyle Jul. 31 at 4:02 AM

$IMRX does anyone know a timeframe when they will report the 3 month readout ?

0 · Reply

a0Br0 Jul. 30 at 11:51 PM

$IMRX is this ah pump just gonna fade in the PM?

0 · Reply

playtrades2day Jul. 30 at 9:48 PM

$IMRX and?

0 · Reply

combat_cannabis Jul. 30 at 7:32 PM

$IMRX I wouldn’t be surprised to see it come back down to 4$ at least once more but probably going to take another entry at last low. 3.86-4$ with a stop loss. Weekly has a lot to reclaim probably needs to settle a minute before reversing.

0 · Reply

combat_cannabis Jul. 30 at 4:02 PM

$IMRX want to see a few days hold this level

0 · Reply

Eruption Jul. 29 at 8:56 PM

$IMRX this is torture. What the actual f***.

0 · Reply

rickahuna Jul. 29 at 7:46 PM

$IMRX Name: Immuneering Study Team Phone Number: 860-321-1302 Email: [email protected] This study has 31 locations increased locations in Australia, but wondering why no other international locations since pancreatic cancer is highest among wealthier countries especially in Asia.

0 · Reply

JuggernautRaider Jul. 29 at 6:10 PM

$TNXP buying more. The pressure is on. NJ biopharma is for turtles, sharks and orcas. 🐢 🦈 🫍 Hogs, whales, and rabbits get eaten for a reason 🐖 🐋 🐇 Seth is an old doctor who cannot sell Tonmya. The last year has been awful. But the right CEO / CFO will turn this ship around. 🛳️ 🐢 🦈 🫍 🦈 🫍 🚤 🫍 🪨 💥 $ALT $CCCC $IMRX all looking juicy 😋

2 · Reply

OptimistJP Jul. 28 at 11:34 PM

$IMRX Blackrock owns 4,314,766.00 shares. https://ir.immuneering.com/node/9571/html

2 · Reply

JuggernautRaider Jul. 28 at 3:33 PM

$ALT buying more long. This big boy needs some pemvituvide… all the benefits of a GLP-1 at a minimal dose. 9% fat loss!!! $TNXP $IMRX $CCCC ALL DAY SON! 🏀 BUY THE MF DIP!! 🏦 do your own damn due diligence and don’t be a baby or impatient and you’ll be just fine 🇺🇸

0 · Reply

combat_cannabis Jul. 28 at 2:52 PM

$IMRX wasn’t ready, all good. Lost nothing. Waiting for a better entry till I’m convinced it’s ready. Still a great name

0 · Reply

Eruption Jul. 28 at 2:18 PM

$IMRX Unreal. Truly unreal. Last September, over . Today, going to 4. Those "investment" classes I took were absolute garbage and useless.

0 · Reply

combat_cannabis Jul. 27 at 5:52 PM

$IMRX

0 · Reply

combat_cannabis Jul. 27 at 5:12 PM

$IMRX try and entry here with stop loss under 4.30 if it doesn’t hold up I’ll wait again for another entry

0 · Reply

Market Cap	267.20M
Revenue (ttm)	0.00
Net Income (ttm)	-56.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	497,500
Avg Vol	1,702,044
Day's Range	N/A - N/A
Shares Out	64.70M
Stochastic %K	29%
Beta	0.41
Analysts	Strong Sell
Price Target	$17.67